Umang Vohra Appointed Executive Chairman and Group CEO of Cohance Lifesciences Limited

Umang Vohra Appointed Executive Chairman and Group CEO of Cohance Lifesciences Limited​

Hyderabad, April 27, 2026 Cohance Lifesciences Limited, a technology-driven, integrated CDMO platform, announced the appointment of Umang Vohra as Executive Chairman and Group CEO. Mr. Vohra is scheduled to assume the role of Executive Chairman effective May 1, 2026, and Group CEO effective May 20, 2026.

The appointment marks a strategic move by the Board, aiming to bring in a leader whose profile is deemed suitable for the company's next phase of transformation and continued growth. Mr. Vohra succeeds Mr. Vivek Sharma, who has stepped down as Executive Chairman for personal reasons. Mr. Sharma will continue to support Cohance as an Advisor for the next nine months, ensuring a smooth transition.

Cohance Lifesciences operates as a CDMO platform specializing in complex chemistry, ADCs, oligonucleotides, and advanced API development and performance materials. The company has established a differentiated position in the global CDMO landscape through its strength in proprietary chemistry, complex multi-step synthesis, and advanced process R&D. Its capabilities encompass complex APIs, ADCs, Oligonucleotides, complex intermediates, performance materials, and specialty ingredients. The platform is supported by integrated R&D centers, over 400 R&D scientists, and established partnerships with global pharmaceutical innovators.

Umang Vohra is a highly accomplished leader with a career spanning more than three decades in the pharmaceutical industry. Most recently, as CEO and Managing Director of Cipla Limited, Mr. Vohra guided the company's transformation over the past decade into a diversified global pharmaceutical enterprise. His experience transforming two large and respected Pharma companies in India is noted for bringing an owner-mindset and extensive business experience to Cohance.

Umang Vohra stated, "I am very excited to be joining Cohance. I believe deeply in the long-term value creation potential of this platform. Cohance's technology offerings, depth of its R&D talent, and the quality of the leadership team already in place provide a strong foundation. I am looking forward to this entrepreneurial stint and will work closely with the current management leaders to create value for customers, employees and shareholders alike."

Addressing the transition, Vivek Sharma commented, "Over the past few years, we have built a strong foundation for Cohance integrating businesses, strengthening the leadership team, and establishing the platform's identity as a science-led CDMO. I am proud of what the team has achieved and confident that the platform is well positioned for its next chapter. I wish Umang and the entire Cohance team every success as they take the company forward."

Pankaj Patwari, Managing Director at Advent, expressed enthusiasm for the new leadership, stating, "The platform will greatly benefit from a leader like Umang, who brings an owner-manager mindset, and who can build on the business's scientific foundation, drive commercial scale, deepen customer partnerships, and develop a leading operating culture. We are delighted to partner with him as we continue to grow the business together."

Cohance Lifesciences Limited is publicly listed on the BSE and NSE in India and is majority owned by Advent. The company offers development and manufacturing solutions for global pharmaceutical and life sciences customers, focusing on complex APIs, performance materials, Ag chem, ADCs, Oligonucleotides, and advanced chemistries.

COHANCE Stock Price Movement​

Shares of COHANCE LIFESCIENCES LIMITED are rallying as of 9:15 AM, trading at ₹380.35, up 5.62% in live market action. The stock is seeing active trading interest, with 50,062 shares changing hands in the morning session.